Health Care · Life Sciences Tools & Services
Danaher: revenue, profit and cash flow
In fiscal 2025, Danaher had revenue of $24.6B, up 2.0% a year on average since 2020, and net income of $3.61B (14.7% of revenue).
Revenue, fiscal 2025
average annual revenue growth since 2020 · +2.9% vs 2024
- Ticker
- DHR · NYSE
- Sector
- Health Care
- Sub-industry
- Life Sciences Tools & Services
- Headquarters
- Washington, D.C.
- Founded
- 1969
- In the S&P 500 since
- November 18, 1998
- Latest fiscal year
- 2025, ended December 31, 2025
- SEC filer
- Danaher Corp /De · CIK 0000313616
Revenue and net income
Revenue went from $15.5B in 2017 to $24.6B in 2025.
Diluted earnings per share
Diluted EPS went from $2.10 in 2007 to $5.05 in 2025. Ten-year growth: 0.6% a year.
Shares outstanding
1.1% more shares in 2025 than in 2015 (708M → 716M): new shares outweighed buybacks.
Operating cash flow, capex and free cash flow
Free cash flow (operating cash flow minus capital expenditure) was $5.26B in 2025, 21.4% of revenue.
The chart data could not be loaded. The table below has the same figures.
Year by year
| Fiscal year | Revenue | Net income | Net margin | Diluted EPS | Shares | Operating cash flow | Capex | Free cash flow |
|---|---|---|---|---|---|---|---|---|
| 2025 | $24.6B | $3.61B | 14.7% | $5.05 | 716M | $6.42B | $1.16B | $5.26B |
| 2024 | $23.9B | $3.9B | 16.3% | $5.29 | 737M | $6.69B | $1.39B | $5.3B |
| 2023 | $23.9B | $4.76B | 19.9% | $6.38 | 743M | $7.16B | $1.38B | $5.78B |
| 2022 | $26.6B | $7.21B | 27.1% | $9.66 | 737M | $8.52B | $1.12B | $7.4B |
| 2021 | $24.8B | $6.43B | 25.9% | $8.61 | 737M | $8.36B | $1.24B | $7.12B |
| 2020 | $22.3B | $3.65B | 16.4% | $4.89 | 719M | $6.21B | $791M | $5.42B |
| 2019 | $17.9B | $3.01B | 16.8% | $4.05 | 726M | $3.95B | $636M | $3.32B |
| 2018 | $17B | $2.65B | 15.5% | $3.74 | 710M | $4.02B | $584M | $3.44B |
| 2017 | $15.5B | $2.49B | 16.1% | $3.53 | 706M | $3.48B | $571M | $2.91B |
| 2016 | — | $2.55B | — | $3.65 | 700M | $3.52B | $590M | $2.93B |
| 2015 | — | $3.36B | — | $4.74 | 708M | $3.8B | $513M | $3.29B |
| 2014 | — | $2.6B | — | $3.63 | 716M | $3.76B | $465M | $3.29B |
| 2013 | — | $2.69B | — | $3.80 | 711M | $3.59B | $538M | $3.05B |
| 2012 | — | $2.39B | — | $3.36 | 713M | $3.42B | $458M | $2.96B |
| 2011 | — | $2.17B | — | $3.11 | 701M | $2.63B | $334M | $2.29B |
| 2010 | — | $1.79B | — | $2.64 | 683M | $2.08B | $191M | $1.89B |
| 2009 | — | $1.15B | — | $1.73 | 671M | $1.8B | $175M | $1.63B |
| 2008 | — | $1.32B | — | $1.98 | 672M | $1.86B | $194M | $1.67B |
| 2007 | — | $1.37B | — | $2.10 | 659M | $1.65B | $162M | $1.48B |
Fiscal years, labelled by the year in which they end. US dollars; per-share figures and share counts adjusted for splits. —: not in the data.
Stock splits
Found in the filings; per-share figures and share counts on this page are on today’s share basis.
- 2-for-1 split · first reflected in a filing of August 11, 2010
About these figures
- No dividends per share in the filings data. Usually that means no dividend, but some companies report theirs in a form the data do not capture.
- Older years are as filed at the time and may predate later restatements, mergers or spin-offs. How the figures are made.
Other Life Sciences Tools & Services companies
Source: SEC EDGAR (company filings), data as of November 8, 2026. Sectors, sub-industries, headquarters and index dates: Wikipedia, CC BY-SA 4.0.